Current Report Filing (8-k)
September 07 2018 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 4, 2018
Aquinox Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36327
|
|
98-0542593
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
450 887 Great Northern Way,
Vancouver, B.C.
Canada,
V5T 4T5
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code:
(604) 629-9223
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 1.02
|
Termination of a Material Definitive Agreement
|
On September 4, 2018, Astellas US LLC, a subsidiary of Astellas Pharma Inc. (Astellas) provided notice to
Aquinox Pharmaceuticals, Inc. (the Company) that Astellas was terminating the exclusive license and collaboration agreement that had been entered into between the Companys wholly owned subsidiary Aquinox Pharmaceuticals (Canada)
Inc. and Astellas on May 9, 2018 (the Astellas Agreement). The termination of the Astellas Agreement will be effective March 4, 2019, unless an earlier termination date is agreed to by the parties. The termination follows the
Companys June 27, 2018 announcement that its Phase 3 LEADERSHIP 301 clinical trial evaluating once-daily, oral rosiptor
(AQX-1125)
for the treatment of interstitial cystitis/bladder pain syndrome
(IC/BPS) failed to meet its primary endpoint, and that the Company had halted all further development activities with rosiptor.
Under the Astellas Agreement, the Company had granted Astellas an exclusive, royalty-bearing license to use, research,
develop, manufacture and commercialize rosiptor and related compounds for all human diseases and conditions in Japan and certain other countries in the Asia-Pacific region, as more fully described in the Companys Current Report on Form
8-K
filed on May 10, 2018, and qualified by the terms and conditions of the actual Astellas Agreement, which was filed as an exhibit to the Companys Quarterly Report on Form
10-Q
for the period ending June 30, 2018.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
Aquinox Pharmaceuticals, Inc.
|
|
|
By:
|
|
/s/ Kamran Alam
|
Name:
|
|
Kamran Alam
|
Title:
|
|
Chief Financial Officer
|
Date: September 7, 2018
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
From Apr 2024 to May 2024
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Aquinox Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Aquinox Pharmaceuticals, Inc News Articles